CY1116167T1 - Φαρμακευτικeς συνθεσεις κατευθυνομενες σε υποδοχεις erb-b1 - Google Patents

Φαρμακευτικeς συνθεσεις κατευθυνομενες σε υποδοχεις erb-b1

Info

Publication number
CY1116167T1
CY1116167T1 CY20151100329T CY151100329T CY1116167T1 CY 1116167 T1 CY1116167 T1 CY 1116167T1 CY 20151100329 T CY20151100329 T CY 20151100329T CY 151100329 T CY151100329 T CY 151100329T CY 1116167 T1 CY1116167 T1 CY 1116167T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical compositions
erb
guided
mab
relates
Prior art date
Application number
CY20151100329T
Other languages
English (en)
Inventor
Hans-Georg Kreysch
Jürgen Schmidt
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CY1116167T1 publication Critical patent/CY1116167T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Abstract

Η εφεύρεση αναφέρεται σε φαρμακευτικές συνθέσεις που περιλαμβάνουν διαφορετικά μόρια, κατά προτίμηση μονοκλωνικά αντισώματα, που το καθένα περιλαμβάνει επιτόπους που δεσμεύονται ταυτόχρονα σε διαφορετικές θέσεις εντός της ίδιας περιοχής του υποδοχέα ErbB 1. Τα προτιμώμενα αντισώματα σύμφωνα με αυτή την εφεύρεση είναι τα MAb 425 και MAb 225 καθένα υπό την μυοειδή, χιμαιρική και ανθρωποποιημένη έκδοση. Η εφεύρεση σχετίζεται με τη χρήση και τις μεθόδους για βελτιωμένη θεραπεία κατά προτίμηση όγκων μέσω των εν λόγω συνθέσεων.
CY20151100329T 2002-10-10 2015-04-06 Φαρμακευτικeς συνθεσεις κατευθυνομενες σε υποδοχεις erb-b1 CY1116167T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02022389 2002-10-10
EP02022390 2002-10-10
EP03757931.5A EP1549344B1 (en) 2002-10-10 2003-10-09 Pharmaceutical compositions directed to erb-b1 receptors

Publications (1)

Publication Number Publication Date
CY1116167T1 true CY1116167T1 (el) 2017-02-08

Family

ID=32095025

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100329T CY1116167T1 (el) 2002-10-10 2015-04-06 Φαρμακευτικeς συνθεσεις κατευθυνομενες σε υποδοχεις erb-b1

Country Status (19)

Country Link
US (2) US7226592B2 (el)
EP (2) EP1549344B1 (el)
JP (3) JP2006505546A (el)
KR (2) KR20050057631A (el)
CN (1) CN1703243B (el)
AU (2) AU2003273964B2 (el)
BR (2) BR0315123A (el)
CA (2) CA2501821C (el)
CY (1) CY1116167T1 (el)
DK (1) DK1549344T3 (el)
ES (1) ES2533963T3 (el)
HK (2) HK1081448A1 (el)
HU (1) HUE025086T2 (el)
MX (2) MXPA05003796A (el)
PL (2) PL210545B1 (el)
PT (1) PT1549344E (el)
RU (2) RU2354402C2 (el)
SI (1) SI1549344T1 (el)
WO (2) WO2004032961A1 (el)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
IL146480A0 (en) * 1999-05-14 2002-07-25 Imclone Systems Inc Treatment of refractory human tumors with epidermal growth factor receptor antagonists
EP1311291A4 (en) * 2000-08-09 2007-07-25 Imclone Systems Inc TREATMENT OF HYPERPROLIFERATIVE DISEASES USING EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS
AU2002219221B2 (en) * 2001-01-09 2007-05-17 Merck Patent Gmbh Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
ATE446317T1 (de) 2001-05-11 2009-11-15 Ludwig Inst For Cancer Res Ltd Spezifische bindungsproteine und ihre verwendung
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US7696320B2 (en) * 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
SI1549344T1 (sl) * 2002-10-10 2015-05-29 Merck Patent Gmbh FARMACEVTSKI SESTAVKI PROTI RECEPTORJEM ErbB1
US8505468B2 (en) * 2002-11-19 2013-08-13 Sharp Kabushiki Kaisha Substrate accommodating tray
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP2332990A1 (en) * 2004-03-19 2011-06-15 Imclone LLC Human anti-epidermal growth factor receptor antibody
AU2005250216B2 (en) 2004-06-01 2009-12-10 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
NI200800032A (es) 2005-07-25 2009-03-23 Reducción de célula b utilizando moléculas de unión específicas cd37 y cd20
EA200801171A1 (ru) * 2005-12-06 2008-12-30 Домантис Лимитед Биспецифичные лиганды, обладающие специфичностью связывания с поверхностными клеточными мишенями, и способы их применения
EA015173B1 (ru) * 2006-01-04 2011-06-30 Мерк Патент Гмбх Комбинированная терапия с использованием антител к egfr и her2
US20110165150A1 (en) * 2006-01-18 2011-07-07 Merck Patent Gmbh Isolated organ perfusion combination therapy of cancer
US7498142B2 (en) * 2006-01-31 2009-03-03 Yeda Research And Development Co., Ltd. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
WO2007123661A2 (en) 2006-03-31 2007-11-01 Massachusetts Institute Of Technology Treatment of tumors expressing mutant egf receptors
EP2094268A2 (en) * 2006-05-26 2009-09-02 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
MX2008015524A (es) 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Proteinas de union multivalentes monocatenarias con funcion efectora.
AU2007353412A1 (en) 2006-11-21 2008-11-20 Fox Chase Cancer Center Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
JP5276017B2 (ja) 2007-01-25 2013-08-28 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｅｇｆｒ変異体仲介性疾患の治療における抗ｅｇｆｒ抗体の使用
AU2013200209B9 (en) * 2007-03-01 2015-07-09 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
JP5726417B2 (ja) * 2007-03-01 2015-06-03 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ 組み換え抗上皮成長因子受容体抗体組成物
CN101688229B (zh) 2007-03-15 2013-06-12 路德维格癌症研究所 包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
CN101896503B (zh) 2007-08-14 2018-05-22 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
EP2190878A1 (en) 2007-09-06 2010-06-02 Genmab A/S Novel methods and antibodies for treating cancer
EP2193149A1 (en) * 2007-10-02 2010-06-09 Merck Patent GmbH Crystalline egfr - matuzumab complex and matuzumab mimetics obtained thereof
WO2009070753A2 (en) * 2007-11-28 2009-06-04 The Scripps Research Institute Bivalent single chain fv antibody compositions that specifically bind to integrin receptor on a metastatic cell in a mammalian subject
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
BRPI0821906B1 (pt) 2008-01-03 2022-06-07 The Scripps Research Institute Anticorpo isolado de comprimento total, seu uso, polinucleotideo, vetor, e célula hospedeira
SI2132228T1 (sl) 2008-04-11 2011-10-28 Emergent Product Dev Seatle CD37 imunoterapevtik in kombinacija z njegovim bifunkcionalnim kemoterapevtikom
CA2732856C (en) * 2008-08-29 2018-08-28 Symphogen A/S Cancer treatment with a combination of two different anti-epidermal growth factor receptor antibodies
WO2010029534A1 (en) 2008-09-15 2010-03-18 Yeda Research And Development Co. Ltd. Antibody combinations and use of same for treating cancer
EP2362783A2 (en) 2008-10-31 2011-09-07 Biogen Idec MA Inc. Light targeting molecules and uses thereof
AR075896A1 (es) 2009-03-20 2011-05-04 Genentech Inc Anticuerpos anti-her (factor de crecimiento epidermico)
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
EP2417156B1 (en) * 2009-04-07 2015-02-11 Roche Glycart AG Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CN104945509A (zh) 2009-09-16 2015-09-30 弗·哈夫曼-拉罗切有限公司 包含卷曲螺旋和/或系链的蛋白质复合体及其用途
JP5832437B2 (ja) * 2009-10-14 2015-12-16 アコーダ セラピューティクス インコーポレイテッド 末梢神経損傷を処置するためのニューレグリンの使用
MX2012006406A (es) 2009-12-04 2012-07-25 Genentech Inc Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos.
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
AU2011248088B2 (en) 2010-05-04 2015-06-25 Merrimack Pharmaceuticals, Inc. Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
EP2576621B1 (en) 2010-05-27 2019-04-10 Genmab A/S Monoclonal antibodies against her2
EP2575880B1 (en) 2010-05-27 2019-01-16 Genmab A/S Monoclonal antibodies against her2 epitope
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
WO2012024659A2 (en) * 2010-08-20 2012-02-23 Massachusetts Institute Of Technology Antibody-based constructs directed against tyrosine kinase receptors
JP5758004B2 (ja) 2010-08-24 2015-08-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ジスルフィドによって安定化されたＦｖ断片を含む二重特異性抗体
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
AU2012211014A1 (en) 2011-01-24 2013-05-02 National Research Council Of Canada Antibodies selective for cells presenting EGFR at high density
MX342034B (es) 2011-02-28 2016-09-12 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos.
BR112013019975A2 (pt) 2011-02-28 2017-08-01 Hoffmann La Roche proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
WO2012143524A2 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
US9040047B2 (en) 2011-05-16 2015-05-26 Yeda Research And Development Co. Ltd. Combinations of anti ErbB antibodies for the treatment of cancer
CN106432506A (zh) 2011-05-24 2017-02-22 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
WO2013119966A2 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
CA2872226A1 (en) 2012-05-02 2013-11-07 Symphogen A/S Humanized pan-her antibody compositions
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
JP6203838B2 (ja) 2012-06-27 2017-09-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 少なくとも２つの異なる結合実体を含む、テーラーメイドの高度に選択的かつ多重特異的なターゲティング実体を選択および作製するための方法、ならびにその使用
EP2912062A1 (en) * 2012-10-24 2015-09-02 Yeda Research and Development Co. Ltd. Combinations of epidermal growth factor receptor targeting antibodies for treating cancer
CN105073776B (zh) 2012-11-13 2019-04-12 拜恩科技股份公司 用于治疗表达紧密连接蛋白的癌症疾病的制剂
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CN105451767B (zh) 2013-03-15 2019-10-18 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
KR102089591B1 (ko) 2013-07-29 2020-03-18 삼성전자주식회사 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
EP3055329B1 (en) 2013-10-11 2018-06-13 F. Hoffmann-La Roche AG Multispecific domain exchanged common variable light chain antibodies
WO2015073721A1 (en) 2013-11-13 2015-05-21 Zymeworks Inc. Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof
MX2016006572A (es) 2013-11-27 2016-12-09 Zymeworks Inc Construcciones de union a antigenos biespecificas dirigidas a her2.
MA39599A (fr) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage et administration d'agents thérapeutiques anti-egfr
SG11201703309PA (en) * 2014-10-31 2017-05-30 Baylor College Medicine Survivin specific t-cell receptor targeting tumor but not t cells
WO2016065456A1 (en) * 2014-10-31 2016-05-06 Formation Biologics Inc. Egfr antibody-based combination therapy
PL3227332T3 (pl) 2014-12-03 2020-06-15 F. Hoffmann-La Roche Ag Wielospecyficzne przeciwciała
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
CR20180161A (es) 2015-10-02 2018-05-25 Hoffmann La Roche Anticuerpos biespecíficos para pd1 y tim3
EP3356821B1 (en) * 2015-10-02 2019-10-23 H. Hoffnabb-La Roche Ag Cellular based fret assay for the determination of simultaneous binding
BR112019014147A2 (pt) * 2017-01-09 2020-02-11 Biomunex Pharmaceuticals Ligante polipeptídico para a preparação de anticorpos multiespecíficos
PL3606946T3 (pl) 2017-04-03 2022-11-28 F. Hoffmann-La Roche Ag Immunokoniugaty przeciwciała anty-PD-1 ze zmutowaną IL-2 lub z IL-15
BR112019019821A2 (pt) 2017-04-05 2020-04-22 Hoffmann La Roche anticorpo biespecífico, polinucleotídeo, célula hospedeira procariótica ou eucariótica, métodos de produção do anticorpo biespecífico, de tratamento de um indivíduo que tem câncer ou uma infecção viral crônica e de inibição do crescimento de células de tumor, composição farmacêutica e uso do anticorpo biespecífico
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5705157A (en) * 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
JP3854306B2 (ja) * 1991-03-06 2006-12-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ヒト化及びキメラモノクローナル抗体
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
JPH05320513A (ja) * 1992-05-26 1993-12-03 Toray Dow Corning Silicone Co Ltd 粘土状オルガノポリシロキサン組成物
CA2120745A1 (en) * 1992-06-30 1994-01-06 Philip G. Kasprzyk A combination of anti-erbb-2 monoclonal antibodies and method of using
US6342219B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
AU2001264946A1 (en) * 2000-05-24 2001-12-03 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
AU2002219221B2 (en) * 2001-01-09 2007-05-17 Merck Patent Gmbh Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
US7132511B2 (en) * 2001-02-19 2006-11-07 Merck Patent Gmbh Modified anti-EGFR antibodies with reduced immunogenicity
SI1549344T1 (sl) * 2002-10-10 2015-05-29 Merck Patent Gmbh FARMACEVTSKI SESTAVKI PROTI RECEPTORJEM ErbB1

Also Published As

Publication number Publication date
RU2005114482A (ru) 2006-01-27
US20060165685A1 (en) 2006-07-27
CA2501821A1 (en) 2004-04-22
CN1703243A (zh) 2005-11-30
HUE025086T2 (en) 2016-02-29
CA2501818A1 (en) 2004-04-22
PL210545B1 (pl) 2012-01-31
US20060002920A1 (en) 2006-01-05
JP2006505546A (ja) 2006-02-16
SI1549344T1 (sl) 2015-05-29
HK1081448A1 (en) 2006-05-19
RU2354402C2 (ru) 2009-05-10
PT1549344E (pt) 2015-04-15
JP2010280727A (ja) 2010-12-16
CN1703243B (zh) 2011-05-04
CA2501818C (en) 2012-03-27
EP1549344B1 (en) 2015-01-07
JP2006505545A (ja) 2006-02-16
AU2003273964B2 (en) 2009-11-19
EP1549344A1 (en) 2005-07-06
JP5179702B2 (ja) 2013-04-10
KR101088661B1 (ko) 2011-12-01
AU2003273964A1 (en) 2004-05-04
BR0315123A (pt) 2005-08-16
MXPA05003796A (es) 2006-02-22
PL374586A1 (en) 2005-10-31
RU2005114480A (ru) 2006-02-10
PL374587A1 (en) 2005-10-31
US7226592B2 (en) 2007-06-05
RU2349340C2 (ru) 2009-03-20
US7638125B2 (en) 2009-12-29
BR0315117A (pt) 2005-08-16
WO2004032961A1 (en) 2004-04-22
WO2004032960A1 (en) 2004-04-22
KR20050057631A (ko) 2005-06-16
AU2003276084B2 (en) 2009-07-09
DK1549344T3 (en) 2015-04-07
HK1081449A1 (en) 2006-05-19
CA2501821C (en) 2012-08-14
MXPA05003795A (es) 2005-06-08
KR20050062612A (ko) 2005-06-23
AU2003276084A1 (en) 2004-05-04
EP1549345A1 (en) 2005-07-06
ES2533963T3 (es) 2015-04-16

Similar Documents

Publication Publication Date Title
CY1116167T1 (el) Φαρμακευτικeς συνθεσεις κατευθυνομενες σε υποδοχεις erb-b1
CY1120065T1 (el) Ανθρωπινα αντισωματα για ton erbb 2
CY1120252T1 (el) Μορια δεσμευσης αντιγονου με αυξημενη συγγενεια προσδεσης στον υποδοχεα fc και λειτουργια τελεστη
CY1115675T1 (el) Αντισωματα κατα cd40
CY1121451T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα κατα του ctla-4
CY1118955T1 (el) Anti-il-6 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
CY1107708T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης
CY1118369T1 (el) Αντισωματα εναντι cd38 για την θεραπεια πολλαπλου μυελωματος
DE602006013029D1 (de) Anti-egfr-antikörper
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1118063T1 (el) ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ΑΝΘΡΩΠ1ΝΗΣ IgE ΥΨΗΛΗΣ ΣΥΓΓΕΝΕΙΑΣ
RS80704A (en) ANTI- av?6.ANTIBODIES
TR199902878T2 (xx) Tip II TGF-Beta Resept�r/�m�noglob�lin sabit b�l�m f�zyon proteinleri.
CY1106662T1 (el) Αντι-igf-ir αντισωματα και οι εφαρμογες τους
CY1112750T1 (el) Ανθρωπινα μονοκλωνα αντισωματα εναντια στο cd20
ATE377027T1 (de) Tetravalente antikörperkonstrukte
CY1112507T1 (el) Μορια αντισωματος που εχουν ειδικοτητα για την ανθρωπινη ιl-1β
WO2020082209A8 (zh) 抗cldn18.2抗体及其用途
CY1114050T1 (el) Μονοκλωνικα αντισωματα εναντι claudin-18 στην αγωγη εναντι καρκινου
ZA200508389B (en) Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
WO2003034903A3 (en) Psma antibodies and protein multimers
CA2469833A1 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
EA202192090A1 (ru) Антигенсвязывающие белки против гамма-цепи рецептора il2